Name | 4-(7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzothiazepin-12-yl)benzoic acid |
---|---|
Synonyms |
hx 630
unii-n564s742u1 |
Description | HX630 is a potent retinoic acid X receptor (RXR) agonist, can induce apoptosis, has anti-tumor effect, and can be used in Cushing's disease research[1]. |
---|---|
Related Catalog | |
In Vitro | HX630 (0.1-10 μM, 96 h) 可以剂量依赖性的抑制细胞增殖诱导 AtT20 细胞凋亡[1]。 Cell Viability Assay[1] Cell Line: AtT20 cells Concentration: 0.1, 1, 5, 10 μM Incubation Time: 96 h Result: Significantly inhibited AtT20 cell proliferation at 10 μM. Decreased Pomc mRNA expression and ACTH secretion in a dose-dependent manner. |
In Vivo | HX630(5 mg/kg,腹腔注射,每周 3 次,持续 3 周)在感染了AtT20 细胞的 BALB/c-nu 小鼠模型中,可以减少肿瘤的生长[1]。 Animal Model: Female BALB/c-nu mice (nu/nu) with AtT20 cells[1] Dosage: 5 mg/kg Administration: i.p., 3 times a week for 3 weeks Result: Significantly reduced tumor volume and Pomc mRNA expression in tumor cells, but body weight and plasma ACTH levels were not significantly different. |
References |
Molecular Formula | C28H27NO2S |
---|---|
Molecular Weight | 441.58 |
Exact Mass | 441.17600 |
PSA | 74.96000 |
LogP | 6.80310 |